Related Experiment Video
Updated: May 28, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Factors Associated with Referral to Expert Providers among Patients with Pulmonary Hypertension
Kari R Gillmeyer1,2, Seppo T Rinne3,2,4, Justin M Rucci1,2
1Center for Health Optimization and Implementation Research, VA Boston Healthcare System, Boston, Massachusetts.
Abstract:
Rationale: Guidelines recommend early referral to pulmonary hypertension experts for patients with confirmed or suspected pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), among others. Yet patients often have advanced disease at the time of referral. The drivers of these referral delays are not well known. Objectives: Building on our prior qualitative findings on barriers to timely pulmonary hypertension care along the care continuum, we sought to identify patient-level factors associated with referral to pulmonary hypertension experts. Methods: We leveraged the Massachusetts All-Payer Claims Database to identify all patients with incident pulmonary hypertension from 2015 to 2017 using a validated algorithm (sensitivity 28%, specificity 100%) and further identified subgroups with risk factors for PAH and CTEPH. Our outcome was the presence or absence of referral to a pulmonary hypertension expert during the study period. On the basis of our prior qualitative work, our three primary exposures were 1) Medicaid enrollment, 2) mental health diagnoses, and 3) distance to the nearest pulmonary hypertension center. We conducted separate multivariable logistic regression models to determine the association between each of our primary exposures and outcome, among our entire cohort and among those with risk factors for PAH and CTEPH. Results: Among our entire cohort (n = 12,505), 704 (5.6%) were seen by pulmonary hypertension experts. Among the subset with risk factors for PAH (n = 2,393) and CTEPH (n = 3,167), 242 (10.1%) and 185 (5.8%) were seen by pulmonary hypertension experts, respectively. Patients less likely to be referred included Medicaid recipients (adjusted odds ratio [aOR], 0.64 [95% confidence interval (CI), 0.53-0.77]), those with mental health diagnoses (aOR, 0.69 [95% CI, 0.58-0.83]), and those living further from a pulmonary hypertension center (aOR, 0.78 [95% CI, 0.74-0.82] for each 10-mile increase in distance to a pulmonary hypertension center). Findings were similar among those with risk factors for PAH and CTEPH. Conclusions: Few patients with pulmonary hypertension are referred to pulmonary hypertension experts, including those with risk factors for PAH and CTEPH. Factors associated with expert referral identified in this study highlight barriers to timely pulmonary hypertension care and offer targeted areas of future study to improve the timeliness of pulmonary hypertension care.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

